The significance of the alteration of 8-OHdG in serous ovarian carcinoma by unknown
Xu et al. Journal of Ovarian Research 2013, 6:74
http://www.ovarianresearch.com/content/6/1/74RESEARCH Open AccessThe significance of the alteration of 8-OHdG in
serous ovarian carcinoma
Xia Xu1, Yan Wang2, Wenwen Guo3,4, Yiqing Zhou5, Chunmei Lv6, Xiaoxiang Chen6,7* and Kaijiang Liu8*Abstract
Background: Oxidative damage and DNA repair dysfunction are associated with carcinogenesis. 8-OHdG is one of
the major oxidative DNA adducts. Present work aims to investigate whether the expression of 8-OHdG and its key
repair gene hOGG1 play distinctive role in two types of serous ovarian cancer.
Materials and methods: 8-OHdG level in DNA from tumor and matched tumor-adjacent normal tissue in 48 high-
grade papillary serous carcinomas (HG-SOC), 24 low-grade papillary serous carcinomas (LG-SOC), 20 serous cystadenomas,
and 16 non-tumor control ovaries was tested. The Cox proportional hazards model and the log-rank test were used to
assess the associations between the 8-OHdG level in two types of serous cancer and patients’ survival. Real-time
polymerase chain reaction and protein immunoblot were employed to detect hOGG1 mRNA and protein levels in
tumor and adjacent normal tissues. Immunohistochemistry was used to determine the expression of hOGG1 and p53.
Results: There was no difference of average 8-OHdG/106dG DNA level either between HG-SOC (27.8 ± 8.9), LG-SOC
(25.2 ± 7.4) and benign serous cystadenoma (26.5 ± 7.7, p = 0.35); or between the tumor-adjacent normal tissue of
HG-SOC (18.8 ± 5.2), LG-SOC (21.4 ± 6.5), benign serous cystadenoma (20.5 ± 9.1) and non-tumor ovary (21.6 ± 4.9,
p = 0.62). The 8-OHdG/106dG level was significantly higher in tumor comparing to that in matched normal tissue
adjacent to carcinoma in HG-SOC (1.52 ± 0.52, p = 0.02), but not in LG-SOC or benign serous cystadenoma. Increased
level of 8-OHdG in tumor DNA was an independent factor of overall survival in serous ovarian carcinoma upon
multivariate analysis (p < 0.01). Increased level of 8-OHdG in tumor DNA indicates poorer overall and progression-free
survival durations than counterparts (47.3 vs 105.7 months and 13.5 vs 45.3 months, respectively). Protein levels of
hOGG1 were remarkably decreased in HG-SOC (p < 0.01), but not in LG-SOC and serous cystadenoma compared with
the tissue adjacent to carcinoma. A positive result on p53 immunostaining was associated with lower hOGG1 expression
in HG-SOC (p = 0.04).
Conclusion: Increased 8-OHdG level and decreased expression of hOGG1 in tumor were found in HG-SOC but not
LG-SOC. Increased 8-OHdG level in tumor DNA was significantly associated with poorer overall survival and progression-
free survival in serous ovarian carcinoma.
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Epithelial ovarian cancer (EOC) is the most lethal
gynecological malignancy in USA, and the second rank
in China while the incidence rate of EOC is evidently in-
creasing during the past decades [1,2]. The fact that the
more aggressive high-grade subgroup accounts for more* Correspondence: cxxxxcyd@Gmail.com; Liukaijiang@renji.com
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reproduction in any medium, provided the orthan 50% of EOCs is regarded as the major reason for
the poor survival rate of this disease [3-5]. A recent de-
fined model revealed that high-grade serous ovarian car-
cinoma (HG-SOC) can progress through greater genetic
instability that leads to rapid metastasis without an identi-
fiable precursor lesion aside from a stepwise mutation
process in low-grade serous ovarian carcinoma (LG-SOC)
[6]. HG-SOC was thought to be driven predominantly by
multiple amplification and deletion; and nearly all cases
have inactivating mutations of p53 [7], whereas 40% ex-
hibit mutations of BRCA1 or BRCA2 [8], while LG-SOCThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics of the population in the
present study
Characteristic n (%)/median (range)
Age (years) 61.2 years (26.0 - 82.5)
BMI (index) 26.3 (17.2 - 36.7)
Histology, n = 108
HG-SOC 48(44.4 %)
LG-SOC 24(22.2 %)
Serous cystadenoma 20(18.5 %)
Normal ovary 16(14.8 %)





HG-SOC, High-grade serous ovarian cancer.
LG-SOC, Low-grade serous ovarian cancer.
BMI, Body mass index.
FIGO, International federation of gynecology and obstetrics.
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hibits activating mutations of Ras, Raf, and PTEN.
Defects in response to DNA damage was one of the cen-
tral pathogeneses of human malignancies [9]. BRCA1 and
BRCA2, involved in DNA repair and cellular response to
DNA damage, were reported to be responsible for approxi-
mately 5% to 10% of EOCs in patients with a family history
[10]. However, whether other DNA repair-associated genes
confer risk to the development of sporadic EOC remains
uncertain. The genetic variation in base excision repair
(BER) system-induced genetic instability linked to ma-
lignancy susceptibility is substantial at present [11,12].
The 8-hydroxy-2′-deoxyguanosine (8-OHdG) is one
of the best-characterized oxidized bases. 8-OHdG in
DNA could lead to mis-incorporation of adenines op-
posite the 8-OHdG lesion thus inducing G:C to T:A muta-
tions in genomic DNA. 8-oxoguanine DNA glycosylase 1
(OGG1), a bifunctional glycosylase, is mainly involved in
repairing 8-OHdG from oxidative damage. Polymor-
phisms and loss of heterozygozity of hOGG1 gene, as sus-
ceptibility factors for sporadic EOC, have been revealed in
several case–control studies [13-16]. In our previous
study, we found that variations in the 5′UTR of hOGG1
gene conferred risk to type II but not to type I EOC [17].
We also suggested that hOGG1 variations are more fre-
quent in p53 positive breast and ovarian cancer [18,19].
Studies revealed that increasing 8-OHdG level is asso-
ciated with higher stage and non-optimal surgical out-
come in EOC [20,21], and may confer risk to high grade
subtype. Comprehensive mapping of TP53 mutation
rates in a homogeneous group of EOC patients revealed
that mutant TP53 is a driver mutation in HG-SOC patho-
genesis [22]. However, there was still no evidence ex-
ploring the relationship between 8-OHdG or hOGG1
alteration and the p53 mutation in serous ovarian cancer.
In the present study, we explored 8-OHdG level and
compared hOGG1 mRNA and protein levels in the two
types of SOC, benign serous cystadenomas, and normal
ovaries (non-tumor control). We also analyzed the rela-
tionship between 8-OHdG expression and the survival
in serous ovarian cancer. To eliminate differences in
base repair ability among individuals, a match pair study
of tumor and adjacent non-tumor tissue was conducted.
Materials and methods
Subjects and samples
All patients were clinically diagnosed sporadic ovarian
tumor and underwent primary treatment in the Depart-
ment of Gynecologic Oncology, Jiangsu Institute of Can-
cer Research (JICR), the University of Nanjing Medical
University between January 2003 and December 2010.
The exclusion criterions were summarized as below:
histology confirmed to be other than ovarian tumor; a
history of prior cancer, diabetes; an inability to giveinformed consent, or was either pregnant or breastfeed-
ing. Patients were genetically unrelated ethnic Han
Chinese women from Nanjing City and its surrounding
regions. All subjects had complete clinical data or
follow-up information as shown in Table 1.
Tumor and matched non-tumors ovarian tissues were
collected from 24 LG-SOCs, 48 HG-SOC, 20 serous
cystadenomas, and 16 non-tumor control ovaries. The
median age of patients was 55 years (38 to 77 years).
Samples were preserved in RNAlater reagent (QIAGEN)
and stored at −80°C until further analysis. Tumor adja-
cent non-tumor tissue is defined as at least 1 cm far
away from cancer tissue boundary and pathologically
confirmed non-tumor. Normal samples were pathologic-
ally excluded tumor in ovary. All resection specimens
were reviewed by two pathologists from JICR (XY. Xu
and N. Hou). Tumor tissues available for 8-OHdG level,
mRNA and protein expression assays were all tissue slides
confirmed for quality control. The study was approved by
the Local Ethic Committee of the Jiangsu Cancer Institute,
and each patient provided a written consent.
8-OHdG levels in genomic DNA of tissue
Based on the salting out method, DNA extraction from
normal ovary, tumor, and adjacent non-tumor tissues
(10 mL, with EDTA added to prevent coagulation) was
performed within one hour after collection. Eppendorf
BioPhotometer Plus (Eppendorf, North America) was
used to check the purity of the DNA sample through
OD260 nm/OD280 nm, and OD260 nm/OD230 nm.
After dissolving into 135 μL water, DNA (200 μg) was
mixed with sodium acetate (15 μL, 200 mM) and nucle-
ase P1 (15 μL, 6 units, Sigma, USA) and incubated at
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buffer (15 μL, 1 M, pH 7.4) and alkaline phosphatase
(7 μL, 2 units, TAKARA, Shiga, Japan) were added. An
ELISA kit (Highly Sensitive 8-OHdG Check, JaICA,
Fukuroi, Shizuoka, Japan) was used to measure 8-OHdG
according to protocol. Results were converted to 8-OHdG/
106 dG according to a previously reported method [23].
Immunohistochemical staining for hOGG1 and p53 in EOC
Polyclonal anti-hOGG1 (1:1000, Novus Biologicals, NB
100–106) and monoclonal anti-p53 (1:100, Novocastra,
DO-7) antibodies were obtained commercially. Mouse
IgG prepared against glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) was obtained from Chemicon
International, Inc. (Temecula, CA). The hOGG1 immu-
nostaining results were divided semiquantitatively into
four groups: 0 = no immunostaining present; 1 = weak
immunostaining (< 10% positive staining cells); 2 = mod-
erate immunostaining (10-50% positive staining cells); 3 =
strong immunostaining (> 50% positive staining cells). We
define “0”, “1” as “negative” and “2”, “3” as “positive” [24].
Immunohistochemical analysis of paraffin-embedded
section (IHC-P) staining of p53 was assessed semi-
quantitatively using a previously reported standard [17].
Ten percent of neoplastic cells were used as a cutoff from
negative expression for p53 immunostaining. Staining
evaluation was performed by two independent pathologists.
hOGG1 expression through protein immunoblot
In accordance with the instructions for the total protein
extraction kit, total protein was extracted from 100 mg
specimens. Protein concentrations were assayed via the
Bradford method, and specimens were adjusted to the
same protein concentration, packaged, and preserved at
−70°C for later use. With a prestained marker serving as
an index, required gels were selected after polyacryl-
amide gel electrophoresis was performed, and a nitrocel-
lulose filter was used for the transfer print. The primary
antibody concentration was 1:1000 and the secondary
antibody was 1:2000. Using alkaline phosphatase color-
ation, the protein hybridization band was scanned with a
GIS-2020 digital image analysis system and the absorbance
value was assayed. The ratios of hOGG1 and GAPDH
were calculated for the semi-quantitative analysis.
hOGG1 mRNA expression from EOC tissue
Total RNA from tissue samples was extracted using Tri-
zol (Invitrogen, Carlsbad, CA) and ethanol precipitation,
according to the instructions of the manufacturer.
Primers and probes for hOGG1 mRNAs were 5′-TGA
CACCTCACCTCACCCAC-3′, 5′-CACTGTCTTCCGC
AAGTTCAC −3′, and TaqMan 5′ (6-FAM)-ACCCTG
GTCCGAGGTGTCCCTGAG-(TAMRA-Q) 3′. Primers
for β-actin mRNA were 5′- CCAACCGCGAGAAGATGA−3′ and 5′- CCAGAGGCGTACAGGGATAG −3′. Ana-
lysis of hOGG1 expression was carried out via RT-PCR.
Quantitative detection of hOGG1 mRNA was performed
using the Quantitect Multiplex RT-PCR Kit (QIAGEN),
following the instructions of the manufacturer. Reaction
was performed in a 25 μL solution containing 1x Master
mix, 0.25 μL RT mix, 0.4 μM of each primer pair, 0.2 μM
probe, and 250 ng RNA. Reaction mixture was reversely
transcribed at 50°C for 20 min, and heated at 95°C for
15 min before being amplified, using 40 cycles of thermo
cycling, with each cycle at 94°C for 45 s and at 60°C for
1.15 min. Samples were normalized based on β-actin
mRNA content. Amplification of β-actin was also per-
formed using the kit form QIAGEN. PCR was performed
in a 20 μL solution containing 1x SYBR RT Master Mix
buffer, 0.2 μL Quantitect RT mix, 0.4 μM of each primer,
and 200 ng RNA. PCR occurred following reverse tran-
scription at 50°C for 20 min and heating at 95°C for 15 min
through 35 cycles of amplification, with each cycle at 94°C
for 15 s, 48°C for 20 s, and 72°C for 30 s. Tissue samples
with more than 150 copies of β-actin mRNA were used for
hOGG1 mRNA analyzing (Additional file 1: Figure S1,
Additional file 2: Figure S2 and Additional file 3: Figure S3).
Statistical analysis
All statistical analyses were carried out using the statis-
tical program SPSS version 13.0. Descriptive statistical
values included mean ± SD values for continuous data
and percentages for categorical data. Differences in pro-
tein and mRNA levels as well as in 8-OHdG concentra-
tions among subgroups were evaluated using the student
t-test, and t-test was used for categorical variables such
as immunostaining results. In all cases, a p value of less
than 0.05 was considered as statistically significant. The
Cox proportional hazards model was used to assess the
association between overall survival and clinicopatholog-
ical characteristics including the 8-OHdG level. The
Kaplan–Meier estimate was calculated by the log-rank
test for overall survival and progression-free survival,
values stratified by 8-OHdG alteration.
Results
8-OHdG levels increased in HG-SOC compared to tumor-
adjacent normal tissue
8-OHdG levels in tissue DNA were not statistically dif-
ferent in HG-SOC (27.8 ± 8.98/106dG), LG-SOC (25.2 ±
7.4/106dG), and benign serous cystadenoma (26.5 ± 7.7/
106dG; Figure 1, p = 0.35). There was no difference in a
parallel investigation of tumor-adjacent normal tissue in
HG-SOC (18.8 ± 5.2/106dG), LG-SOC (21.4 ± 6.5/106dG),
benign serous cystadenoma (20.5 ± 9.1/106dG) and non-
tumor ovary (21.6 ± 4.9/106dG; Figure 1, p = 0.62). Higher
fold of 8-OHdG expression in the tumor compared with
that in the normal tissue adjacent to carcinoma was found
Figure 1 8-OHdG DNA levels in tumors and matched adjacent normal tissues of HG-SOC, LG-SOC, serous cystadenoma, and normal
ovaries (mean ± SEM).
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(Figure 2, p = 0.02).
hOGG1 gene expression was lower in HG-SOC compared
to tumor-adjacent normal tissue
hOGG1 mRNA expression
There was no difference of hOGG1 mRNA levels among
HG-SOC, LG-SOC, and serous cystadenoma using RT-
PCR analysis (p = 0.52, Figure 3). No difference was notedFigure 2 8-OHdG, hOGG1 mRNA and protein expression alteration in
serous cystadenoma, and normal ovaries (mean ± SEM) (T, tumor tissuamong the tumor-adjacent normal tissues from HG-SOC,
LG-SOC, serous cystadenoma, and normal control (p =
0.37, Figure 3). hOGG1 mRNA level in tumors decreased
compared with tumor-adjacent normal tissues in HG-SOC,
but there was no statistical significance (p = 0.09, Figure 2).
hOGG1 protein immunoblot
There was no difference of hOGG1 protein expression in
HG-SOC, LG-SOC, and serous cystadenoma (p = 0.31,tumors and matched adjacent normal tissues of HG-SOC, LG-SOC,
e; A, adjacent normal tissue).
Figure 3 hOGG1 mRNA levels in tumors and matched adjacent normal tissues of HG-SOC, LG-SOC, serous cystadenoma, and normal
ovaries (mean ± SEM).
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including HG-SOC, LG-SOC, serous cystadenoma, and
normal control (p = 0.60, Figure 4). hOGG1 protein ex-
pression level in tumors decreased compared with tumor-
adjacent normal tissues and the degree was more remark-
able in HG-SOC than in LG-SOC and serous cystade-
noma (p < 0.01, Figure 2).Figure 4 hOGG1 protein expression in tumors and matched adjacent
normal ovaries (mean ± SEM). hOGG1 and GAPDH are apparent at 39P53 positive-staining is associated with lower hOGG1
expression in HG-SOC
Negative IHC-P staining of hOGG1 was more frequently in
HG-SOC than in LG-SOC and serous cystadenoma; how-
ever, no statistical significance (p = 0.19, Figure 5) was noted.
Compared with that of LG-SOC, the positive-staining
rate of p53 in HG-SOC tissues was significantly highernormal tissues of HG-SOC, LG-SOC, serous cystadenoma, and
kDA and 37 kDa, respectively.
Figure 5 IHC-P analysis of hOGG1 protein expression in serous ovarian cancer: (A) Normal ovarian tissue treated with anti-hOGG1 antibody,
biotinylated anti-rabbit IgG secondary antibody, and avidin-biotin-peroxidase complex, and counterstained with p-dimethylaminobenzaldehyde
reagent (magnification 100 x); (B) serous cystadenoma with positive staining (magnification 200 x); (C) LG-SOC tissue with moderate positive staining
(magnification 200 x); and (D) HG-SOC with negative staining (magnification 200 x). Black arrow pointed at the immunostained epithelial cells.
Table 2 p53 correlated with hOGG1 expression in ovarian
cancer
Subgroup p53 immunostaining hOGG1(+) hOGG1(−) p value
LG-SOC (+) 4(16.7 %) 1(4.2 %) 0.55
(−) 15(62.5 %) 4(16.7 %)
HG-SOC (+) 10(20.8 %) 26(54.2 %) 0.04
(−) 8(16.7 %) 4(8.3 %)
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associated with hOGG1 lower expression in HG-SOC
(p = 0.04) but not in LG-SOC (p = 0.55, Table 2).
Increasing 8-OHdG level is associated with poor
prognosis in serous ovarian cancer
The Cox proportional hazards analysis revealed that in-
creasing 8-OHdG level independently associated with
overall survival in serous ovarian cancer (p < 0.01,
Table 3). We further found that increasing 8-OHdG
level (p = 0.03 and p = 0.001, Figure 6), but not hOGG1
expression alteration (Additional file 4: Figure S4), in
tumor was associated with shorter overall and progres-
sion free survivals.
Discussion
EOC is a serious health problem among the female
population worldwide. Type II subtype of this tumor is
responsible for 90% of deaths associated with this dis-
ease, and it has different tumorigenesis with type I pa-
tients. HG-SOC, the major subtype of type II ovarian
cancer, is associated with p53 mutation and decreased
ability of DNA damage repair [25,26]. We observed in
HG-SOC, but not in LG-SOC and serous cystadenoma,
that the average 8-OHdG/106dG level was significantly
higher in tumor DNA, and protein expression of
hOGG1 was remarkably decreased in the tumors, com-
pared with those in matched non-tumor tissues. The sta-
tus of p53 immunostaining was also associated with
hOGG1 expression in HG-SOC.Base excision repair, as one of the major DNA damage
repair systems, includes several enzymes with coopera-
tive and compensatory enzymatic activities and further
associated with the susceptibility of tumor develop-
ments. It’s difficult for intuitively estimating the weight
of one enzyme dysfunction as an alternative to the over-
all repair ability. Our results show that no difference
existed between hOGG1 mRNA and protein expressions
among HG-SOC, LG-SOC, and serous cystadenoma, as
well as between tumor-adjacent tissues and normal ovar-
ies. Previous studies led to conflicting conclusions on
the relationship between hOGG1 expression and cancer
risk. Li et al. [27] found that normal breast tissues from
cancer patients had a significantly higher level of oxida-
tive DNA damage. The elevated level of 8-oxo-dG in
cancer patients was not related to deficiency of the
hOGG1 expression. Other studies reported that hOGG1
gene expression was markedly suppressed in up to 38%
of head and neck squamous cell carcinomas [28,29]. In
the present research, we used paired specimens from tumor
and adjacent non-tumor tissue to eliminate individual
Table 3 8-OHdG alteration associated with overall survival of serous ovarian cancer patients (N = 72)
Characteristic Univariate analysis p value Multivariate analysis p value
HR 95 % CI HR 95 % CI
FIGO stage
I 1.00 Reference 1.00 Reference
II 1.42 0.68-6.25 1.21 0.43-8.02
III 6.78 1.66-18.41 2.25 1.24-6.08
IV 9.43 3.61-27.87 <0.01 3.28 1.47-9.54 <0.01
Grade 4.12 1.35-12.69 <0.01 2.57 1.62-3.45 <0.01
Suboptimal CRS 2.16 1.25-3.85 <0.01 1.65 1.19-2.55 0.02
Ascites 1.47 1.26-3.04 0.01 1.23 1.08-2.36 0.04
Nadir CA-125 level 1.02 1.01-1.04 <0.01 1.01 1.00-1.03 <0.01
p53 positive 1.30 1.09-4.39 0.02 1.13 0.96-2.41 0.10
8-OHdG (T/A) 1.35 1.13-3.42 <0.01 1.18 1.01-2.07 <0.01
hOGG1 protein (T/A) 0.84 0.78-1.06 0.54 0.89 0. 88–1.02 0.65
Age 1.01 1.00-1.01 0.04 1.00 0.98-1.01 0.21
HR, Hazard ratio; CI, Confidence interval; CRS, Cytoreductive surgery. T/A, Tumor/Adjacent non-tumor tissue.
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tein expression were associated with the grade of SOC.
Serous carcinoma was reported to be correlated with
p53 mutation [30]. Diminished base excision repair was
also reported in p53 mutant and p53-null cells [31].
These cells exhibited very low activity of DNA β-
polymerase, an enzyme required for repair. Immunohis-
tochemical positive status of p53 is commonly thought
to correlate closely with mutation status and lost the ac-
tivity as the tumor suppresses the gene. We found that
p53 positive immunostaining is related to decreasing
protein level of hOGG1 in HG-SOC. Does p53 dysfunc-
tion induce a decrease in hOGG1 expression, or vice
versa? Hence, further studies are needed to test the
causality relationship between p53 mutation and hOGG1
expression on the carcinogenesis of HG-SOC.Figure 6 Increasing 8-OHdG expression in tumor DNA is associated w
(A) 8-OHdG level associated with overall survival; (B) 8-OHdG level associatThis study also has several drawbacks. Firstly, tumor
tissues and adjacent normal tissues were mostly sampled
from surgical biopsies. 8-OHdG level and hOGG1 ex-
pression might have been influenced by neo-adjuvant
chemotherapy in several cases, though our experiment
had controls. Secondly, in spite of having tissue slide
sections for quality control, non-tumor cells such as
lymphocytes and fibroblasts may interfere in tumor cells
during 8-OHdG and hOGG1 assays, which also affected
the accuracy of our results. Thirdly, increase in oxidative
damage products and decrease in damage repair ability
linked with advancement in age was reported to be asso-
ciated with age-related diseases [32,33]. Meanwhile, HG-
SOC patients were relatively older than LG-SOC cases
[34]. Is this a satellite phenomenon that requires serious
consideration?ith poor prognosis of serous ovarian cancer patients (N = 72).
ed with progression-free survival.
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series of enzymes in DNA repair pathways, especially
the BER for DNA single-strand breaks repair. Inhibition
of PARPs can lead to cell death and genomic instability
in DNA repair-defective tumors (like those with
BRAC1/2 mutations), what is so called "synthetic lethal-
ity". Hooten et al. [35] identified an interaction between
two DNA repair proteins, OGG1 and poly (ADP-ribose)
polymerase 1 (PARP-1). They provided evidence that
cells are more sensitive to PARP inhibitors as a single
agent or in combination with a DNA-damaging agent,
H2O2, in the absence of OGG1. These data imply that
an identified DNA glycosylase dysfunction or a concurrent
hOGG1-targeted therapy may possibly help in clinical tri-
als involving patients with BRCA1/2-mutated or not ovar-
ian carcinoma treated with PARP inhibitors [36-39].
In conclusion, we believe that defects in hOGG1 expres-
sion and increase in 8-OHdG levels may have significant
influences in the development of HG-SOC. 8-OHdG and
hOGG1 levels may be used as molecular markers to dis-
tinguish the two types of SOC. Moreover, specific genetic
or regulation abnormalities in different EOC subtypes
may help in the development of specific drugs.
Additional files
Additional file 1: Figure S1. Electrophoresis of RT-PCR products
of hOGG1.
Additional file 2: Figure S2. Amplification plot of hOGG1 mRNA
level assay.
Additional file 3: Figure S3. Melt curve of hOGG1 mRNA level assay.
Additional file 4: Figure S4. hOGG1 protein expression is not
associated with prognosis of serous ovarian cancer patients (N = 72).
(A) hOGG1 protein level is not associated with overall survival; (B) hOGG1
protein level is not associated with progression-free survival.
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